Embryonal Tumor With Multilayered Rosettes
PNOC031: Protocol for Embryonal Tumor With Multilayered Rosettes (ETMR)
University of California, San Francisco
70 participants
Mar 6, 2025
INTERVENTIONAL
Conditions
Summary
This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo RT
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Undergo surgery directly before study enrollment as part of planned care.
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor tissue will be collected for correlative studies
Blood samples will be collected for correlative studies
CSF samples will be collected for correlative studies
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06861244